GPR35 Inhibitor
Ulcerative Colitis
PreclinicalActive
Key Facts
About ThirtyFiveBio
ThirtyFiveBio is a preclinical-stage biotech developing first-in-class GPR35 inhibitors as a novel, orthogonal treatment for ulcerative colitis (UC). The company's science is built on human genetic validation and a patient-centric biology approach, targeting the protection of the gut epithelium to address a core disease mechanism not tackled by current anti-inflammatory therapies. With a preclinical candidate selected and a patent portfolio filed, the company is advancing through late preclinical activities and is targeting clinical proof-of-mechanism by 2028. It is seeking a syndicated Series A financing round in the second half of 2025 to fund this translation.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |
| '1805 | Revolo Biotherapeutics | Phase 2 (Planned) |